Spots Global Cancer Trial Database for Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma

Official Title: Phase II Study of Bevacizumab Combined With Capecitabine and Oxaliplatin (CAPOX) in Patients With Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

Study ID: NCT01208103

Conditions

Ampulla of Vater Adenocarcinoma

Small Intestinal Adenocarcinoma

Stage III Ampulla of Vater Cancer AJCC v8

Stage III Small Intestinal Adenocarcinoma AJCC v8

Stage IIIA Ampulla of Vater Cancer AJCC v8

Stage IIIA Small Intestinal Adenocarcinoma AJCC v8

Stage IIIB Ampulla of Vater Cancer AJCC v8

Stage IIIB Small Intestinal Adenocarcinoma AJCC v8

Stage IV Ampulla of Vater Cancer AJCC v8

Stage IV Small Intestinal Adenocarcinoma AJCC v8

Interventions

Bevacizumab

Capecitabine

Oxaliplatin

Study Description

Brief Summary: This phase II trial studies how well bevacizumab given with capecitabine and oxaliplatin work in treating participants with small bowel or ampulla of Vater adenocarcinoma that has spread to other places in the body. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Drugs using in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving bevacizumab, capecitabine, and oxaliplatin may work better in treating participants with small intestinal or ampulla of Vater adenocarcinoma.

Detailed Description: PRIMARY OBJECTIVES: I. To determine the progression-free survival (PFS) at six months for patients with advanced adenocarcinoma of the small bowel (small intestine) or ampulla of Vater treated with capecitabine, oxaliplatin (CAPOX) and bevacizumab. SECONDARY OBJECTIVES: I. To determine the response rate (RR) for CAPOX and bevacizumab. II. To determine the overall progression free survival for CAPOX and bevacizumab. III. To determine the overall survival (OS) for CAPOX and bevacizumab. IV. To determine the toxicity of CAPOX and bevacizumab. OUTLINE: Participants receive oxaliplatin via central venous catheter (CVC) over 2 hours and bevacizumab intravenously (IV) over 30-90 minutes on day 1. Participants also receive capecitabine orally (PO) twice daily (BID) on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, participants are followed up at 10 and 30 days, and then every 3 months thereafter.